BeiGene, a Beijing company focused on novel oncology drugs, revealed plans to raise $126.5 million in an IPO on the NASDAQ exchange in early February; Cocoon Networks of China set up shop in London with $707 million to fund innovative companies, including life science; China's iCarbonX, a big data AI healthcare startup, is raising $106 million in initial funding; CASI Pharma, with operations in the US and China, closed $10.3 million of a $25 million round; Shanghai's WuXi Healthcare Ventures announced two investments in US biopharma companies; Gedeon Richter, a Hungarian pharma, acquired 50% of its China JV from its partner; Perennial Real Estate Holdings of Singapore plans to build integrated healthcare hubs in 20 to 40 Chinese cities; and Boston's NeuroMetrix received CFDA approval to market its diagnostic test for diabetic peripheral neuropathy in China.
